Lockdown Never Stopped; Resumption of Work Increases Efficiency
As an integrated preclinical CRO, Medicilon is fully aware of the responsibility to provide continuous R&D services for pharmaceutical companies, research institutions and researchers around the world, especially during the epidemics.
On the evening of March 27, right before the lockdown, Medicilon immediately launched the emergency plan in order to maintain the regular R&D work. The leaders of each R&D department took the lead in setting an example, and the directors and employees at all levels responded one after another. They arrived at the company overnight and stayed at the company until now. They made sure that s all the projects were progressing steadily and orderly.
In response to the guidelines for resumption of work and production, Medicilon has formulated the “Resumption of Work and Production Plan” with 6 major parts, including resumption process, employee return process, epidemic prevention and control work plan, production and operation work plan, the application for resumption of work, and closed operation management. Medicilon will take multiple measures to create a safe and stable R&D environment and ensure the safety of personnel returning to work.
Share：
Relevant
news
marketing@medicilon.com
